Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Int. braz. j. urol ; 42(4): 685-693, July-Aug. 2016. tab, graf
Article in English | LILACS | ID: lil-794682

ABSTRACT

ABSTRACT Background: Bladder cancer represents one of the most important clinical challenges in urologic practice. In this context, inflammation has an important role in the development and progression of many malignancies. The objective of the present study was to evaluate the prognostic value of pre-treatment Neutrophil to lymphocyte ratio (NLR) on the risk of recurrence and progression in patients with primary non-muscle invasive bladder cancer. Materials and Methods: Data obtained from 178 bladder cancer patients who underwent transurethral resection of bladder tumor (TURB) between July 2008 and December 2014 were evaluated prospectively. NLR was obtained from each patient before TURB and defined as the absolute neutrophil count divided by the absolute lymphocyte count. Cox proportional hazards regression model was performed to calculate disease recurrence and progression including NLR. Results: During the follow-up study (median: 53 months), 14 (23.3%) and 44 (37.9%) (p=0.04) patients respectively with NLR<3 and ≥3experienced recurrence and 2 (3.3%) and 14 (11.9%) experienced progression (p=0.06), respectively. At the multivariate Cox regression analysis, NLR ≥3 was associated with worse disease recurrence (HR: 2.84; p<0.01). No association was found regarding disease progression. The 5-year recurrence free survival was 49% and 62% in patients with NLR≥3 and <3 (p<0.01). The 5-year progression free survival was 77% and 93% in patients with NLR≥3 and <3 (p=0.69). Conclusion: NLR predicts disease recurrence but not disease progression in NMIBC patients. NLR alterations may depend of tumor inflammatory microenvironment.


Subject(s)
Humans , Male , Female , Aged , Urinary Bladder Neoplasms/blood , Lymphocytes , Biomarkers, Tumor/blood , Neutrophils , Prognosis , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/pathology , Blood Cell Count , Survival Analysis , Follow-Up Studies , Lymphocyte Count , Disease-Free Survival , Italy/epidemiology , Leukocyte Count , Neoplasm Invasiveness
2.
Int. braz. j. urol ; 42(3): 422-430, tab, graf
Article in English | LILACS | ID: lil-785733

ABSTRACT

ABSTRACT Benign prostatic hyperplasia and prostate cancer are two common urological diseases of the elderly. Scientific community has always looked for a link that could explain the correlation between the two diseases and the role of chronic inflammation in the pathogenesis of BPH and PCa. As shown by the reports of the two diseases relationship with oxidative stress and metabolic syndrome, the use of compounds with antioxidant action could therefore affect both the symptoms and their onset. Polyphenols appear to act not only against oxidative stress but also at different levels. The aim of this review is to evaluate the role of the most important polyphenols on these two urological diseases. As antioxidants these compounds seems to have a direct action on the cell cycle and hormone function, important for both prostate cancer and BPH. Despite a large number of articles about the relationship of the polyphenols with prostate cancer, very little evidence exists for BPH. Additional clinical trials or meta-analysis are necessary on this topic.


Subject(s)
Humans , Male , Prostatic Hyperplasia/prevention & control , Prostatic Neoplasms/prevention & control , Metabolic Syndrome/prevention & control , Polyphenols/therapeutic use , Antioxidants/therapeutic use , Prostatic Hyperplasia/metabolism , Prostatic Hyperplasia/drug therapy , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/drug therapy , Treatment Outcome , Oxidative Stress/drug effects , Metabolic Syndrome/drug therapy
3.
Int. braz. j. urol ; 40(3): 322-329, may-jun/2014. tab, graf
Article in English | LILACS | ID: lil-718248

ABSTRACT

Purpose To evaluate outcomes of patients with high risk prostate cancer (PCa) who underwent radical prostatectomy (RP) in a context of a multidisciplinary approach including adjuvant radiation (RT) + androgen deprivation therapy (ADT). Matherials and Methods 244 consecutive patients with high risk localized PCa underwent RP and bilateral extended pelvic lymph node dissection at our institution. Adjuvant RT + 24 months ADT was carried out in subjects with pathological stage ≥ T3N0 and/or positive surgical margins or in patients with local relapse. Results After a median follow-up was 54.17 months (range 5.4-117.16), 13 (5.3%) subjects had biochemical progression, 21 (8.6%) had clinical progression, 7 (2.9%) died due to prostate cancer and 15 (6.1%) died due to other causes. 136 (55.7%) patients did not receive any adjuvant treatment while 108 (44.3%) received respectively adjuvant or salvage RT+ADT. Multivariate Cox proportional hazard analysis showed that pre-operative PSA value at diagnosis is a significant predictive factor for BCR (HR: 1.04, p < 0.05) and that Gleason Score 8-10 (HR: 2.4; p<0.05) and PSMs (HR: 2.01; p < 0.01) were significant predictors for clinical progression. Radical prostatectomy group was associated with BPFS, CPFS, CSS and OS at 5-years of 97%, 90%, 95% and 86% respectively, while adjuvant radiation + androgen deprivation therapy group was associated with a BPFS, CPFS and CSS at 5-years of 91%, 83%, 95% and 88%, without any statistical difference. Conclusions Multimodality tailored treatment based on RP and adjuvant therapy with RT+ADT achieve similar results in terms of OS after 5-years of follow-up. .


Subject(s)
Aged , Humans , Male , Middle Aged , Androgen Antagonists/therapeutic use , Prostatectomy/methods , Prostatic Neoplasms/therapy , Combined Modality Therapy , Follow-Up Studies , Neoplasm Grading , Neoplasm Recurrence, Local , Neoplasm Staging , Prospective Studies , Prostate-Specific Antigen/blood , Prostatic Neoplasms/pathology , Risk Assessment , Risk Factors , Radiotherapy, Adjuvant/methods , Time Factors , Treatment Outcome
4.
Int. braz. j. urol ; 39(2): 214-221, Mar-Apr/2013. tab, graf
Article in English | LILACS | ID: lil-676271

ABSTRACT

Objective To evaluate the efficacy of Profluss® on prostatic chronic inflammation (PCI). Materials and Methods We prospectively enrolled 168 subjects affected by LUTS due to bladder outlet obstruction submitted to 12 cores prostatic biopsy for suspected prostate cancer + 2 cores collected for PCI valuation. First group consisted of 108 subjects, with histological diagnosis of PCI associated with BPH and high grade PIN and/or ASAP, randomly assigned to 1:1 ratio to daily Profluss® (group I) for 6 months or to control group (group Ic). Second group consisted of 60 subjects, with histological diagnosis of BPH, randomly assigned to 1:1 ratio to daily Profluss® + α-blockers treatment (group II) for 3 months or to control group (group IIc). After 6 months first group underwent 24 cores prostatic re-biopsy + 2 cores for PCI while after 3 months second group underwent two-cores prostatic for PCI. Specimens were evaluated for changes in inflammation parameters and for density of T-cells (CD3, CD8), B-cells (CD20) and macrophages (CD68). Results At follow-up there were statistical significant reductions of extension and grading of flogosis, mean values of CD20, CD3, CD68 and mean PSA value in group I compared to Ic, while extension and grading of flogosis in group II were inferior to IIc but not statistical significant. A statistically significant reduction in the density of CD20, CD3, CD68, CD8 was demonstrated in group II in respect to control IIc. Conclusions Serenoa repens+Selenium+Lycopene may have an anti-inflammatory activity that could be of interest in the treatment of PCI in BPH and/or PIN/ASAP patients. .


Subject(s)
Aged , Humans , Male , Middle Aged , Carotenoids/therapeutic use , Plant Extracts/therapeutic use , Prostatic Hyperplasia/drug therapy , Prostatitis/drug therapy , Serenoa , Selenium/therapeutic use , Anti-Inflammatory Agents/therapeutic use , B-Lymphocytes , Biopsy , Italy , Macrophages , Neoplasm Grading , Prospective Studies , Prostate-Specific Antigen/blood , Prostatic Hyperplasia/pathology , Prostatitis/pathology , T-Lymphocytes , Treatment Outcome , Urinary Bladder Neck Obstruction/drug therapy , Urinary Bladder Neck Obstruction/etiology
SELECTION OF CITATIONS
SEARCH DETAIL